Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2011

01.06.2011 | Colorectal Cancer

Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study

verfasst von: Terence C. Chua, MBBS, David L. Morris, MD, Akshat Saxena, BSc, Jesus Esquivel, MD, Winston Liauw, MBBS, Joerg Doerfer, MD, Christoph-Thomas Germer, MD, Alexander G. Kerscher, MD, Joerg O. W. Pelz, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate the role of modern systemic therapies and its role as palliative or curative therapy for patients with colorectal peritoneal carcinomatosis with an emphasis on patient selection with the colorectal Peritoneal Surface Disease Severity Score (PSDSS).

Methods

From three specialized treatment centers, patients with colorectal peritoneal carcinomatosis were identified between December 1988 to December 2009 to receive best supportive care, standard, or modern systemic therapies. Intent was classified as palliative or curative (if treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy). Patients were stratified according to the PSDSS. Survival was estimated by the Kaplan–Meier method.

Results

Palliative and curative treatment achieved a median survival of 9 (95% confidence interval [95% CI] 5.9–12.8) and 38 (95% CI 30.2–45.2) months, respectively (P < 0.001). The type of chemotherapy in the palliative and curative group influenced outcome (P < 0.001, P = 0.011, respectively). In the palliative group, PSDSS I/II had a median survival of 24 (95% CI 15.6–32.6) and PSDSS III/IV had a median survival of 6 (95% CI 4.9–8.0) months (P < 0.001). In the curative group, PSDSS I/II had a median survival of 49 (95% CI 40.0–58.3) and PSDSS III/IV had a median survival of 31 (95% CI 20.4–40.9) months (P = 0.002).

Conclusions

Modern systemic therapies were associated with improved outcome in patients with colorectal peritoneal carcinomatosis treated systemically alone or with cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Preoperative evaluation with the PSDSS may improve patient selection and optimize outcomes.
Literatur
1.
Zurück zum Zitat Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.PubMedCrossRef Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.PubMedCrossRef
2.
Zurück zum Zitat Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.PubMedCrossRef Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.PubMedCrossRef
3.
Zurück zum Zitat Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.PubMedCrossRef Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.PubMedCrossRef
4.
Zurück zum Zitat Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
5.
Zurück zum Zitat Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef
6.
Zurück zum Zitat Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRef Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRef
7.
Zurück zum Zitat Chua TC, Saxena A, Schelleken JF, et al. Mortality and morbidity outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251:101–6.PubMedCrossRef Chua TC, Saxena A, Schelleken JF, et al. Mortality and morbidity outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251:101–6.PubMedCrossRef
8.
Zurück zum Zitat Joerg OWP, Alexander S, Aviram N, Werner H, Jesus E. Evaluation of a Peritoneal Surface Disease Severity Score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9–15.CrossRef Joerg OWP, Alexander S, Aviram N, Werner H, Jesus E. Evaluation of a Peritoneal Surface Disease Severity Score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9–15.CrossRef
9.
Zurück zum Zitat Chua TC, Morris DL, Esquivel J. Impact of the Peritoneal Surface Disease Severity Score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing a complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6.PubMedCrossRef Chua TC, Morris DL, Esquivel J. Impact of the Peritoneal Surface Disease Severity Score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing a complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6.PubMedCrossRef
10.
Zurück zum Zitat Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef
11.
Zurück zum Zitat Khatri VP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a panacea or just an obstacle course for the patient? J Clin Oncol. 2010;28:5–7.PubMedCrossRef Khatri VP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a panacea or just an obstacle course for the patient? J Clin Oncol. 2010;28:5–7.PubMedCrossRef
12.
Zurück zum Zitat Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus sytemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62.PubMedCrossRef Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus sytemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62.PubMedCrossRef
13.
Zurück zum Zitat Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat. 2008;40:33–5.PubMedCrossRef Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat. 2008;40:33–5.PubMedCrossRef
14.
Zurück zum Zitat Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.PubMedCrossRef Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.PubMedCrossRef
15.
Zurück zum Zitat Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14:2270–80.PubMedCrossRef Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14:2270–80.PubMedCrossRef
Metadaten
Titel
Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study
verfasst von
Terence C. Chua, MBBS
David L. Morris, MD
Akshat Saxena, BSc
Jesus Esquivel, MD
Winston Liauw, MBBS
Joerg Doerfer, MD
Christoph-Thomas Germer, MD
Alexander G. Kerscher, MD
Joerg O. W. Pelz, MD
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1522-1

Weitere Artikel der Ausgabe 6/2011

Annals of Surgical Oncology 6/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.